Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics

go back to reference Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G, Terracciano L, Tornillo L (2007) HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60:768–772CrossRefPubMed Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G, Terracciano L, Tornillo L (2007) HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60:768–772CrossRefPubMed

go back to reference Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 10:1675–1684CrossRefPubMed Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 10:1675–1684CrossRefPubMed

go back to reference Bui KT, Cooper WA, Kao S, Boyer M (2018) Targeted molecular treatments in non-small cell lung cancer: a clinical guide for oncologists. J Clin Med 7:192PubMedCentralCrossRef Bui KT, Cooper WA, Kao S, Boyer M (2018) Targeted molecular treatments in non-small cell lung cancer: a clinical guide for oncologists. J Clin Med 7:192PubMedCentralCrossRef

go back to reference Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW (2016) Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet 17:257–271CrossRefPubMedPubMedCentral Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW (2016) Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet 17:257–271CrossRefPubMedPubMedCentral

go back to reference Chang CC, Wang YR, Chen SF, Wu CC, Chan NL (2013) New insights into DNA-binding by type IIA topoisomerases. Curr Opin Struct Biol 23:125–133CrossRefPubMed Chang CC, Wang YR, Chen SF, Wu CC, Chan NL (2013) New insights into DNA-binding by type IIA topoisomerases. Curr Opin Struct Biol 23:125–133CrossRefPubMed

go back to reference Chen D, Maruschke M, Hakenberg O, Zimmermann W, Stief CG, Buchner A (2017) TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology 102:e261–e267CrossRef Chen D, Maruschke M, Hakenberg O, Zimmermann W, Stief CG, Buchner A (2017) TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology 102:e261–e267CrossRef

go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132CrossRefPubMed

go back to reference Chen SF, Huang NL, Lin JH, Wu CC, Wang YR, Yu YJ, Gilson MK, Chan NL (2018) Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate. Nat Commun 9:3085PubMedCentralCrossRefPubMed Chen SF, Huang NL, Lin JH, Wu CC, Wang YR, Yu YJ, Gilson MK, Chan NL (2018) Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate. Nat Commun 9:3085PubMedCentralCrossRefPubMed

go back to reference Chou C-P, Huang N-C, Jhuang S-J, Pan H-B, Peng N-J, Cheng J-T, Chen C-F, Chen J-J, Chang T-H (2014) Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions. PLoS ONE 9:e93934PubMedCentralCrossRefPubMed Chou C-P, Huang N-C, Jhuang S-J, Pan H-B, Peng N-J, Cheng J-T, Chen C-F, Chen J-J, Chang T-H (2014) Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions. PLoS ONE 9:e93934PubMedCentralCrossRefPubMed

go back to reference De Resende MF, Vieira S, Chinen LTD, Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I, Pagotty S, Pellionisz PA (2013) Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med 11:36PubMedCentralCrossRefPubMed De Resende MF, Vieira S, Chinen LTD, Chiappelli F, da Fonseca FP, Guimarães GC, Soares FA, Neves I, Pagotty S, Pellionisz PA (2013) Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med 11:36PubMedCentralCrossRefPubMed

go back to reference Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, Paules RS, Downes CS, Kaufmann WK (2001) The human decatenation checkpoint. Proc Natl Acad Sci USA 98:12044–12049CrossRefPubMedPubMedCentral Deming PB, Cistulli CA, Zhao H, Graves PR, Piwnica-Worms H, Paules RS, Downes CS, Kaufmann WK (2001) The human decatenation checkpoint. Proc Natl Acad Sci USA 98:12044–12049CrossRefPubMedPubMedCentral

go back to reference Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, Goldstraw P, Rami-Porta R (2015) The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 10:1515–1522. Eberhardt WE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A, Goldstraw P, Rami-Porta R (2015) The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 10:1515–1522.

go back to reference Farcomeni A (2008) A review of modern multiple hypothesis testing, with particular attention to the false discovery proportion. Stat Methods Med Res 17:347–388CrossRefPubMed Farcomeni A (2008) A review of modern multiple hypothesis testing, with particular attention to the false discovery proportion. Stat Methods Med Res 17:347–388CrossRefPubMed

go back to reference Gao Z, Shi R, Yuan K, Wang Y (2016) Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis. Tumour Biol 37:14979–14987CrossRefPubMed Gao Z, Shi R, Yuan K, Wang Y (2016) Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis. Tumour Biol 37:14979–14987CrossRefPubMed

go back to reference Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51CrossRefPubMed Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51CrossRefPubMed

go back to reference Hao Z, Zhang H, Cowell J (2012) Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biol 33:723–730CrossRef Hao Z, Zhang H, Cowell J (2012) Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumor Biol 33:723–730CrossRef

go back to reference Hershko A (1997) Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 9:788–799CrossRefPubMed Hershko A (1997) Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 9:788–799CrossRefPubMed

go back to reference Huang WT, Yang X, He RQ, Ma J, Hu XH, Mo WJ, Chen G (2019) Overexpressed BSG related to the progression of lung adenocarcinoma with high-throughput data-mining, immunohistochemistry, in vitro validation and in silico investigation. Am J Transl Res 11:4835–4850PubMedCentralPubMed Huang WT, Yang X, He RQ, Ma J, Hu XH, Mo WJ, Chen G (2019) Overexpressed BSG related to the progression of lung adenocarcinoma with high-throughput data-mining, immunohistochemistry, in vitro validation and in silico investigation. Am J Transl Res 11:4835–4850PubMedCentralPubMed

go back to reference Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, Inoue H, Kuwano H, Mori M (2007) Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer 121:33–38CrossRefPubMed Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, Inoue H, Kuwano H, Mori M (2007) Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer 121:33–38CrossRefPubMed

go back to reference Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C (2017) Tracking the evolution of non-small-cell lung cancer. N Engl J Med 376:2109–2121CrossRefPubMed Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C (2017) Tracking the evolution of non-small-cell lung cancer. N Engl J Med 376:2109–2121CrossRefPubMed

go back to reference Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B (2018) Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 36:911–919CrossRefPubMed Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam SS, Reck M, Saqi A, Simoff M, Singh N, Sundaram B (2018) Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 36:911–919CrossRefPubMed

go back to reference Kang X, Song C, Du X, Zhang C, Liu Y, Liang L, He J, Lamb K, Shen WH, Yin Y (2015) PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep 5:17873PubMedCentralCrossRefPubMed Kang X, Song C, Du X, Zhang C, Liu Y, Liang L, He J, Lamb K, Shen WH, Yin Y (2015) PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep 5:17873PubMedCentralCrossRefPubMed

go back to reference Kotera M, Okuno Y, Hattori M, Goto S, Kanehisa M (2004) Computational assignment of the EC numbers for genomic-scale analysis of enzymatic reactions. J Am Chem Soc 126:16487–16498CrossRefPubMed Kotera M, Okuno Y, Hattori M, Goto S, Kanehisa M (2004) Computational assignment of the EC numbers for genomic-scale analysis of enzymatic reactions. J Am Chem Soc 126:16487–16498CrossRefPubMed

go back to reference Kruglyak KM, Lin E, Ong FS (2016) Next-generation sequencing and applications to the diagnosis and treatment of lung cancer. Adv Exp Med Biol 890:123–136CrossRefPubMed Kruglyak KM, Lin E, Ong FS (2016) Next-generation sequencing and applications to the diagnosis and treatment of lung cancer. Adv Exp Med Biol 890:123–136CrossRefPubMed

go back to reference Li B, Cui Y, Diehn M, Li R (2017) Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 3:1529–1537PubMedCentralCrossRefPubMed Li B, Cui Y, Diehn M, Li R (2017) Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 3:1529–1537PubMedCentralCrossRefPubMed

go back to reference McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168:613–628CrossRefPubMed McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168:613–628CrossRefPubMed

go back to reference Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11:685–696CrossRefPubMed Meyerson M, Gabriel S, Getz G (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11:685–696CrossRefPubMed

go back to reference Nitiss JL (2009) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9:327–337PubMedCentralCrossRefPubMed Nitiss JL (2009) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9:327–337PubMedCentralCrossRefPubMed

go back to reference Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schönau A, Overgaard J (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43:35–42CrossRefPubMed Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schönau A, Overgaard J (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43:35–42CrossRefPubMed

go back to reference Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol 52:103–109CrossRefPubMed Osmani L, Askin F, Gabrielson E, Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol 52:103–109CrossRefPubMed

go back to reference Ozsolak F, Milos PM (2011) RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 12:87–98CrossRefPubMed Ozsolak F, Milos PM (2011) RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 12:87–98CrossRefPubMed

go back to reference Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S (2015) TOP2A amplification and overexpression in hepatocellular carcinoma tissues. BioMed Res Int 2015:381602PubMedCentralPubMed Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S (2015) TOP2A amplification and overexpression in hepatocellular carcinoma tissues. BioMed Res Int 2015:381602PubMedCentralPubMed

go back to reference Passiglia F, Bronte G, Castiglia M, Listi A, Calo V, Toia F, Cicero G, Fanale D, Rizzo S, Bazan V, Russo A (2015) Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? Expert Opin Biol Ther 15:1553–1566CrossRefPubMed Passiglia F, Bronte G, Castiglia M, Listi A, Calo V, Toia F, Cicero G, Fanale D, Rizzo S, Bazan V, Russo A (2015) Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? Expert Opin Biol Ther 15:1553–1566CrossRefPubMed

go back to reference Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503–533CrossRefPubMed Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503–533CrossRefPubMed

go back to reference Rape M, Kirschner MW (2004) Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 432:588CrossRefPubMed Rape M, Kirschner MW (2004) Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature 432:588CrossRefPubMed

go back to reference Relli V, Trerotola M, Guerra E, Alberti S (2019) Abandoning the notion of non-small cell lung cancer. Trends Mol Med 25:585–594CrossRefPubMed Relli V, Trerotola M, Guerra E, Alberti S (2019) Abandoning the notion of non-small cell lung cancer. Trends Mol Med 25:585–594CrossRefPubMed

go back to reference Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M (2017) Immunotherapy in NSCLC: a promising and revolutionary weapon. Adv Exp Med Biol 995:97–125CrossRefPubMed Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M (2017) Immunotherapy in NSCLC: a promising and revolutionary weapon. Adv Exp Med Biol 995:97–125CrossRefPubMed

go back to reference Rybarczyk-Kasiuchnicz A, Ramlau R (2018) Current views on molecularly targeted therapy for lung cancer—a review of literature from the last five years. Kardiochirurgia i torakochirurgia polska 15:119–124PubMedCentralPubMed Rybarczyk-Kasiuchnicz A, Ramlau R (2018) Current views on molecularly targeted therapy for lung cancer—a review of literature from the last five years. Kardiochirurgia i torakochirurgia polska 15:119–124PubMedCentralPubMed

go back to reference Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:822–827PubMedCentralCrossRefPubMed Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14:822–827PubMedCentralCrossRefPubMed

go back to reference Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y, Ding R, Jiang H, He Q, Guo J (2013) High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer 13:192PubMedCentralCrossRefPubMed Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y, Ding R, Jiang H, He Q, Guo J (2013) High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer 13:192PubMedCentralCrossRefPubMed

go back to reference Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA A Cancer J Clin 65:5–29CrossRef Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA A Cancer J Clin 65:5–29CrossRef

go back to reference Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30CrossRefPubMed Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30CrossRefPubMed

go back to reference Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G (2003) HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107:764–772CrossRefPubMed Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G (2003) HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107:764–772CrossRefPubMed

go back to reference Stark R, Grzelak M, Hadfield J (2019) RNA sequencing: the teenage years. Nat Rev Genet Stark R, Grzelak M, Hadfield J (2019) RNA sequencing: the teenage years. Nat Rev Genet

go back to reference Su X, Wan Y, Xie L, Lin X, Zhao H, Ju X, Fang A (2019) Expression of SUMO1P3 compared with SUMO1 is an independent predictor of patient outcome in lung adenocarcinoma. Med Sci Monit 25:6691–6701PubMedCentralCrossRefPubMed Su X, Wan Y, Xie L, Lin X, Zhao H, Ju X, Fang A (2019) Expression of SUMO1P3 compared with SUMO1 is an independent predictor of patient outcome in lung adenocarcinoma. Med Sci Monit 25:6691–6701PubMedCentralCrossRefPubMed

go back to reference Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98–w102PubMedCentralCrossRefPubMed Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98–w102PubMedCentralCrossRefPubMed

go back to reference Tedesco D, Zhang J, Trinh L, Lalehzadeh G, Meisner R, Yamaguchi KD, Ruderman DL, Dinter H, Zajchowski DA (2007) The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. Neoplasia (New York, NY) 9:601CrossRef Tedesco D, Zhang J, Trinh L, Lalehzadeh G, Meisner R, Yamaguchi KD, Ruderman DL, Dinter H, Zajchowski DA (2007) The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. Neoplasia (New York, NY) 9:601CrossRef

go back to reference Thakur MK, Gadgeel SM (2016) Predictive and prognostic biomarkers in non-small cell lung cancer. Semin Respir Crit Care Med 37:760–770CrossRefPubMed Thakur MK, Gadgeel SM (2016) Predictive and prognostic biomarkers in non-small cell lung cancer. Semin Respir Crit Care Med 37:760–770CrossRefPubMed

go back to reference Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, Goo JM, MacMahon H, Naidich D, Nicholson AG, Powell CA, Prokop M, Rami-Porta R, Rusch V, van Schil P, Yatabe Y (2016) The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 11:1204–1223CrossRefPubMed Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, Goo JM, MacMahon H, Naidich D, Nicholson AG, Powell CA, Prokop M, Rami-Porta R, Rusch V, van Schil P, Yatabe Y (2016) The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 11:1204–1223CrossRefPubMed

go back to reference Turajlic S, Sottoriva A, Graham T, Swanton C (2019) Resolving genetic heterogeneity in cancer. Nat Rev Genet 20:404–416CrossRefPubMed Turajlic S, Sottoriva A, Graham T, Swanton C (2019) Resolving genetic heterogeneity in cancer. Nat Rev Genet 20:404–416CrossRefPubMed

go back to reference Vos SM, Tretter EM, Schmidt BH, Berger JM (2011) All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 12:827–841PubMedCentralCrossRefPubMed Vos SM, Tretter EM, Schmidt BH, Berger JM (2011) All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 12:827–841PubMedCentralCrossRefPubMed

go back to reference Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440CrossRefPubMed Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430–440CrossRefPubMed

go back to reference Wang H, Gu R, Tian F, Liu Y, Fan W, Xue G, Cai L, Xing Y (2019) PHLPP2 as a novel metastatic and prognostic biomarker in non-small cell lung cancer patients. Thorac Cancer 10:2124–2132PubMedCentralCrossRefPubMed Wang H, Gu R, Tian F, Liu Y, Fan W, Xue G, Cai L, Xing Y (2019) PHLPP2 as a novel metastatic and prognostic biomarker in non-small cell lung cancer patients. Thorac Cancer 10:2124–2132PubMedCentralCrossRefPubMed

go back to reference Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES (2013) Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 19:6261–6271CrossRefPubMed Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES (2013) Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 19:6261–6271CrossRefPubMed

go back to reference Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284–287PubMedCentralCrossRefPubMed Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284–287PubMedCentralCrossRefPubMed

go back to reference Zheng H, Zhan Y, Zhang Y, Liu S, Lu J, Yang Y, Wen Q, Fan S (2019) Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection. Cancer Med 8:6894–6903PubMedCentralCrossRefPubMed Zheng H, Zhan Y, Zhang Y, Liu S, Lu J, Yang Y, Wen Q, Fan S (2019) Elevated expression of G3BP1 associates with YB1 and p-AKT and predicts poor prognosis in nonsmall cell lung cancer patients after surgical resection. Cancer Med 8:6894–6903PubMedCentralCrossRefPubMed